AR070460A1 - Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen - Google Patents

Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen

Info

Publication number
AR070460A1
AR070460A1 ARP090100604A ARP090100604A AR070460A1 AR 070460 A1 AR070460 A1 AR 070460A1 AR P090100604 A ARP090100604 A AR P090100604A AR P090100604 A ARP090100604 A AR P090100604A AR 070460 A1 AR070460 A1 AR 070460A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
group
independently selected
triazolyl
Prior art date
Application number
ARP090100604A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR070460(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR070460A1 publication Critical patent/AR070460A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP090100604A 2008-02-21 2009-02-20 Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen AR070460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
AR070460A1 true AR070460A1 (es) 2010-04-07

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100604A AR070460A1 (es) 2008-02-21 2009-02-20 Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen

Country Status (23)

Country Link
US (1) US8716483B2 (enExample)
EP (1) EP2260031B1 (enExample)
JP (1) JP5276676B2 (enExample)
KR (1) KR20100117123A (enExample)
CN (1) CN102015693B (enExample)
AR (1) AR070460A1 (enExample)
AU (1) AU2009215534B8 (enExample)
BR (1) BRPI0908120A8 (enExample)
CA (1) CA2714479A1 (enExample)
CL (1) CL2009000394A1 (enExample)
CO (1) CO6300939A2 (enExample)
EC (1) ECSP10010415A (enExample)
ES (1) ES2556353T3 (enExample)
IL (1) IL207530A (enExample)
MX (1) MX2010009268A (enExample)
MY (1) MY152271A (enExample)
NZ (1) NZ587504A (enExample)
PE (1) PE20091491A1 (enExample)
RU (1) RU2525389C2 (enExample)
SG (1) SG188179A1 (enExample)
TW (1) TWI398441B (enExample)
WO (1) WO2009105500A1 (enExample)
ZA (2) ZA201005909B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
EP2316031B1 (en) * 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
EP2448942B1 (en) 2009-07-02 2014-09-24 Merck Sharp & Dohme Corp. FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
WO2011163330A1 (en) * 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
BR112013009823A2 (pt) 2010-10-22 2016-07-05 Bayer Ip Gmbh novos compostos heterocíclicos como pesticidas
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
JP6186434B2 (ja) * 2012-07-18 2017-08-23 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 窒素複素環誘導体及びその医薬品への応用
CN105050598B (zh) * 2012-09-28 2018-04-27 默沙东公司 作为erk抑制剂的新型化合物
US9226922B2 (en) 2012-09-28 2016-01-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014140073A1 (en) * 2013-03-13 2014-09-18 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
JP6427197B2 (ja) 2013-10-03 2018-11-21 クラ オンコロジー， インコーポレイテッド Ｅｒｋの阻害剤および使用方法
WO2015175846A2 (en) * 2014-05-16 2015-11-19 University Of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) * 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
US10577348B2 (en) * 2014-12-18 2020-03-03 Merck Sharp & Dohme Corp. (S)-N-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
WO2016100152A1 (en) 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
HUE049481T2 (hu) 2015-04-03 2020-09-28 Recurium Ip Holdings Llc Spirociklusos vegyületek
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
KR102823105B1 (ko) 2019-12-06 2025-06-20 디3 바이오 (우씨) 컴퍼니, 리미티드 Erk 억제제로서 작용하는 스피로 화합물 및 이의 응용

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
WO1997045412A1 (en) 1996-05-30 1997-12-04 Merck & Co., Inc. A method of treating cancer
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
EP1005361B1 (en) 1997-07-18 2010-01-06 Novo Nordisk Health Care AG USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
EP1200422A2 (en) 2000-02-05 2002-05-02 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
CA2403017A1 (en) 2000-03-15 2001-09-20 Warner-Lambert Company 5-amide substituted diarylamines as mex inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
AU2001290940A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Isoxazoles and their use as inhibitors of erk
ES2279837T3 (es) 2000-11-20 2007-09-01 Scios Inc. Inhibidores de tipo piperidina/piperazina de la quinasa p38.
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
CA2456192A1 (en) 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
DE60238620D1 (de) 2001-08-03 2011-01-27 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
WO2003035626A2 (en) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7304061B2 (en) 2002-04-26 2007-12-04 Vertex Pharmaceuticals Incorporated Heterocyclic inhibitors of ERK2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
ATE378336T1 (de) 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
AU2004221881A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050107386A1 (en) 2003-11-19 2005-05-19 Rama Krishna Narla Methods of treating diseases and disorders by targeting multiple kinases
WO2005063258A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
WO2005100342A1 (en) 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
WO2005100338A1 (en) 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
DK3305776T3 (da) 2004-05-14 2019-12-09 Vertex Pharma Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
WO2005113546A1 (en) 2004-05-14 2005-12-01 Vertex Pharmaceuticals, Incorporated Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
EP1833820A1 (en) 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinase and uses therof
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CA2633023C (en) 2005-12-13 2015-11-24 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
WO2007123186A1 (ja) 2006-04-20 2007-11-01 Takeda Pharmaceutical Company Limited 医薬
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
KR20100025553A (ko) * 2007-06-05 2010-03-09 쉐링 코포레이션 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
SG182187A1 (en) 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
JP2010530421A (ja) 2007-06-18 2010-09-09 シェーリング コーポレイション 複素環化合物およびｅｒｋ阻害剤としてのそれらの使用
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors

Also Published As

Publication number Publication date
JP5276676B2 (ja) 2013-08-28
ECSP10010415A (es) 2010-09-30
CN102015693A (zh) 2011-04-13
RU2525389C2 (ru) 2014-08-10
EP2260031B1 (en) 2015-10-07
ZA201400396B (en) 2014-12-23
TWI398441B (zh) 2013-06-11
CO6300939A2 (es) 2011-07-21
ES2556353T8 (es) 2017-10-13
AU2009215534B8 (en) 2014-07-10
IL207530A0 (en) 2010-12-30
SG188179A1 (en) 2013-03-28
AU2009215534A2 (en) 2010-12-23
AU2009215534A1 (en) 2009-08-27
MY152271A (en) 2014-09-15
TW200948799A (en) 2009-12-01
RU2010138635A (ru) 2012-03-27
AU2009215534B2 (en) 2014-06-26
PE20091491A1 (es) 2009-09-25
CA2714479A1 (en) 2009-08-27
US20110189192A1 (en) 2011-08-04
CL2009000394A1 (es) 2011-02-11
JP2011513225A (ja) 2011-04-28
WO2009105500A1 (en) 2009-08-27
BRPI0908120A2 (enExample) 2017-08-22
US8716483B2 (en) 2014-05-06
MX2010009268A (es) 2010-09-14
CN102015693B (zh) 2014-10-29
BRPI0908120A8 (pt) 2017-10-24
ZA201005909B (en) 2014-03-26
AU2009215534A8 (en) 2014-07-10
IL207530A (en) 2014-08-31
NZ587504A (en) 2012-09-28
KR20100117123A (ko) 2010-11-02
ES2556353T3 (es) 2016-01-15
EP2260031A1 (en) 2010-12-15

Similar Documents

Publication Publication Date Title
AR070460A1 (es) Compuestos inhibidores de erk y composiciones farmaceuticas que los contienen
BRPI0717767A2 (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase
IN2014DN07283A (enExample)
IL198116A0 (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2008007123A3 (en) Pharmaceutical compounds
WO2008036308A3 (en) Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
AR057911A1 (es) Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento
MX2010006421A (es) Compuestos organicos.
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
SMT201300085B (it) Composti di pirrolo
AR067105A1 (es) Moleculas pequenas que contienen boro
PE20091414A1 (es) FURO [3,2-c] PIRIDINA Y TIENO [3,2-c] PIRIDINAS
TW201129564A (en) Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof
AR057209A1 (es) Compuestos para el tratamiento de trastornos inflamatorios y enfermedades microbianas
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
AR080151A1 (es) Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
BRPI0812942A8 (pt) Composto derivado de 3-amino-6 - (1-amino-etil) - tetra-hidropirano, composição farmacêutica e uso de referido composto.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
UY28821A1 (es) Hidrocloruro de (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos.
PH12015502851A1 (en) Curable composition
BRPI0713951B8 (pt) derivados de quinazolina, e composição farmacêutica
RU2011108359A (ru) Фармацевтическая композиция, содержащая производное 1,2-дитиолтиона, для предотвращения или лечения заболевания, обусловленного повышенной экспрессией lxr-альфа
AR059195A1 (es) Compuestos de ciclourea y uso de los mismos
AR058329A1 (es) Derivados de pirazolo (4,3-c) piridina sustituidos activos como inhibidores de quinasa, un metodo para su preparacion y composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant, registration